DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,101,995 | +1.2% | 12,503 | -2.1% | 0.36% | -1.6% |
| Q2 2023 | $3,064,800 | +1.2% | 12,770 | +6.3% | 0.37% | -6.3% |
| Q1 2023 | $3,027,000 | +97450.8% | 12,010 | +2.7% | 0.40% | -6.2% |
| Q4 2022 | $3,103 | -99.9% | 11,691 | +3.6% | 0.42% | -0.9% |
| Q3 2022 | $2,914,000 | +2.7% | 11,287 | +0.9% | 0.42% | +9.8% |
| Q2 2022 | $2,837,000 | -7.2% | 11,187 | +7.3% | 0.39% | +5.7% |
| Q1 2022 | $3,058,000 | +1.4% | 10,425 | +13.7% | 0.37% | +2.5% |
| Q4 2021 | $3,016,000 | +60.8% | 9,166 | +48.8% | 0.36% | +47.5% |
| Q3 2021 | $1,876,000 | +13.4% | 6,162 | -0.0% | 0.24% | +15.2% |
| Q2 2021 | $1,654,000 | +18.8% | 6,163 | -0.4% | 0.21% | +13.5% |
| Q1 2021 | $1,392,000 | +1.2% | 6,187 | 0.0% | 0.18% | -30.7% |
| Q4 2020 | $1,375,000 | +0.3% | 6,187 | -2.8% | 0.27% | -7.9% |
| Q3 2020 | $1,371,000 | +21.3% | 6,362 | -0.5% | 0.29% | +17.9% |
| Q2 2020 | $1,130,000 | +26.5% | 6,391 | -1.0% | 0.25% | +16.0% |
| Q1 2020 | $893,000 | -10.2% | 6,456 | -0.4% | 0.21% | +9.3% |
| Q4 2019 | $994,000 | +4.9% | 6,480 | -1.2% | 0.19% | -1.5% |
| Q3 2019 | $948,000 | +0.2% | 6,562 | -0.8% | 0.20% | -3.0% |
| Q2 2019 | $946,000 | +8.4% | 6,617 | 0.0% | 0.20% | +0.5% |
| Q1 2019 | $873,000 | +27.6% | 6,617 | -0.3% | 0.20% | +15.4% |
| Q4 2018 | $684,000 | -5.0% | 6,634 | 0.0% | 0.18% | +15.9% |
| Q3 2018 | $720,000 | +9.9% | 6,634 | 0.0% | 0.15% | +2.7% |
| Q2 2018 | $655,000 | +252.2% | 6,634 | +251.0% | 0.15% | +241.9% |
| Q1 2018 | $186,000 | +5.7% | 1,890 | -0.6% | 0.04% | +4.9% |
| Q4 2017 | $176,000 | +6.7% | 1,901 | -1.3% | 0.04% | +5.1% |
| Q3 2017 | $165,000 | -13.6% | 1,926 | -14.9% | 0.04% | -15.2% |
| Q2 2017 | $191,000 | +1.1% | 2,264 | +2.3% | 0.05% | 0.0% |
| Q1 2017 | $189,000 | -3.6% | 2,213 | -11.9% | 0.05% | -6.1% |
| Q4 2016 | $196,000 | -11.3% | 2,511 | -11.1% | 0.05% | -12.5% |
| Q3 2016 | $221,000 | -21.4% | 2,824 | +1.4% | 0.06% | -23.3% |
| Q2 2016 | $281,000 | -27.6% | 2,784 | -31.8% | 0.07% | -29.1% |
| Q1 2016 | $388,000 | -5.4% | 4,085 | -7.7% | 0.10% | -5.5% |
| Q4 2015 | $410,000 | -15.1% | 4,425 | -21.9% | 0.11% | -20.4% |
| Q3 2015 | $483,000 | -78.9% | 5,664 | -78.9% | 0.14% | -77.9% |
| Q2 2015 | $2,294,000 | +6.2% | 26,800 | +5.3% | 0.62% | +6.9% |
| Q1 2015 | $2,160,000 | +1.5% | 25,441 | +2.4% | 0.58% | 0.0% |
| Q4 2014 | $2,129,000 | -24.1% | 24,843 | -32.7% | 0.58% | -25.3% |
| Q3 2014 | $2,804,000 | -2.7% | 36,906 | +0.8% | 0.78% | -0.1% |
| Q2 2014 | $2,883,000 | +6.3% | 36,611 | +1.2% | 0.78% | +1.2% |
| Q1 2014 | $2,713,000 | +3.6% | 36,169 | +6.7% | 0.77% | +2.5% |
| Q4 2013 | $2,619,000 | +13.9% | 33,909 | +2.2% | 0.75% | +6.4% |
| Q3 2013 | $2,299,000 | +8.4% | 33,169 | -1.0% | 0.71% | +4.0% |
| Q2 2013 | $2,121,000 | – | 33,509 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |